BENGALURU, July 29 (Reuters) - India's Hetero Labs Ltd said on Wednesday it received local regulatory approval to launch its version of anti-viral drug favipiravir for the treatment of COVID-19.
The drug, priced at 59 rupees (79 cents) per tablet, will be available at drug stores from Wednesday, privately held Hetero said.
($1 = 74.7800 Indian rupees)
(Reporting by Sachin Ravikumar; Editing by Saumyadeb Chakrabarty)
((email@example.com; +91 80 6182 2754; Twitter: @sachinr27;))
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.